Free Trial
NASDAQ:FEMY

Femasys Q3 2024 Earnings Report

Femasys logo
$2.00 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys EPS Results

Actual EPS
-$4.80
Consensus EPS
-$4.00
Beat/Miss
Missed by -$0.80
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.55 million
Expected Revenue
$0.40 million
Beat/Miss
Beat by +$150.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Femasys' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Femasys Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office.

Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure. The company is also developing FemBloc, a non-surgical, investigational permanent birth-control system intended to provide a hormone-free contraceptive option. FemBloc has not been approved for commercial use in the United States.

Headquartered in Atlanta, Georgia, Femasys was founded by Kathy Lee-Sepsick, who serves as the company’s president and chief executive officer. The company primarily develops its products for the U.S. market and has pursued regulatory and commercial opportunities in women’s reproductive health.

View Femasys Profile